ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1353

Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study

Maria Helena Lourenco1, Rita Torres2, Santiago Rodrigues-Manica3, Vanessa Fraga4, Ana Catarina Abreu5, Roberto Costa6, Carolina Ochôa Matos7, Beatriz Mendes8, Beatriz Samões9, Inês Silva1, Fernando Pimentel-Santos10, Manuela Costa1, Jaime Branco11 and Alexandre Sepriano12, 1Hospital Egas Moniz, Lisbon, Portugal, 2Hospital Egas Moniz, Lisboa, Portugal, 3Hospital Egas Moniz, CHLO, Lisboa, Portugal, 4Hospital Garcia de Orta, Nogueira da Regedoura, Portugal, 5Hospital Garcia de Orta, Lisboa, Portugal, 6Centro Hospitalar Lisboa Norte, Lisboa, Portugal, 7Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 8Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 9Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, 10NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, 11CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, 12Leiden University Medical Centre, Portela Loures, Portugal

Meeting: ACR Convergence 2023

Keywords: Sexual Function, SF36, Systemic lupus erythematosus (SLE), Women's health, X-ray

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients’ quality of life (QoL). Sexual (dis)function is a key component of QoL but is often underappreciated. Little is known about sexual disfunction in SLE patients, a condition that primarily affects women during their fertile age.

We aimed at determining the prevalence of sexual dysfunction among women with SLE and predictors thereof.

Methods: We performed a cross-sectional multicenter study in which women (18-70 years-old) with a clinical diagnosis of SLE (according to their treating rheumatologist) were included. An anonymous online questionnaire was perfomed where data on demographics (e.g., age), symptoms of depression and anxiety [Hospital Anxiety and Depression Scale (HADS)), health-related QoL (Short Form Health

Survey Index 36 Item (SF36)]) and sexual function [Female Sexual Function Index (FSFI) – a 19-item patient-report outcome that assesses female sexual function]) were collected. Data on clinical features [disease activity according to the Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), organ involvement and evaluation of comorbidity (Charlson Comorbidity Index)] and on treatment status were collected from medical records. The main outcome was sexual dysfunction, defined as FSFI< 26.5 (validated cut-off). A multivariable logistic regression was perfomed to test the association of clinical and demographic characteristics with sexual dysfunction (present vs absent).

Results: In total, 194 female patients with SLE were included (mean age 44 years-old [standard deviation (SD) 11]). The mean SELENA-SLEDAI score was 1.7 (SD: 2.2), corresponding to low disease activity, and 94% of patients were on classical disease-modifying antirheumatic drugs. The mean value of HADS was 9 (0-21), for both depression and anxiety scores. Regarding SF36, the mental component had a mean value of 61 (0-100) and the physical one of 70 (0-100). Sexual disfunction was present in 128 (66%) patients.

In the multivariable analysis (Table 1), older age (OR: 1.04; 95%CI: 1.01; 1.07), higher SELENA-SLEDAI (OR: 1.18; 95%CI: 1.01; 1.40), higher HADS depression score (OR: 1.20; 95%CI: 1.01; 1.43), as well as a lower (that is, worse) SF36 mental component score (OR: 0.97; 95%CI: 0.95; 0.98) were independently associated with sexual dysfunction.

Conclusion: Sexual disfunction is common in women with SLE and is influenced by both physical and mental health components. Clinicians should consider both for the optimal management of their patients in order to improve their sexual QoL.

Supporting image 1

Descriptive analysis of the population.
SD, standard deviation; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) – systemic lupus erythematosus disease activity index (SLEDAI); cDMARDs, classic disease-modifying anti-rheumatic drugs; bDMARDs, biologic disease-modifying anti-rheumatic drugs

Supporting image 2

Multivariable analysis.
* Not selected in the univariable model (p>0.25); † Not selected in the multivariable model (p>0.05); Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) – systemic lupus erythematosus disease activity index (SLEDAI); CCI, Charlson Comorbidity Index; bDMARDs, biologic disease-modifying anti-rheumatic drugs; cDMARDs, classic disease-modifying anti-rheumatic drugs


Disclosures: M. Lourenco: None; R. Torres: None; S. Rodrigues-Manica: None; V. Fraga: None; A. Abreu: None; R. Costa: None; C. Ochôa Matos: None; B. Mendes: None; B. Samões: None; I. Silva: None; F. Pimentel-Santos: None; M. Costa: None; J. Branco: None; A. Sepriano: None.

To cite this abstract in AMA style:

Lourenco M, Torres R, Rodrigues-Manica S, Fraga V, Abreu A, Costa R, Ochôa Matos C, Mendes B, Samões B, Silva I, Pimentel-Santos F, Costa M, Branco J, Sepriano A. Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sexual-dysfunction-in-women-with-systemic-lupus-erythematosus-a-cross-sectional-multicentre-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sexual-dysfunction-in-women-with-systemic-lupus-erythematosus-a-cross-sectional-multicentre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology